Yusuke Mizukami

Dr. Yusuke Mizukami

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YMYusuke Mizukami
Yusuke Mizukami
WJWon-Seok Jo
Won-Seok Jo
EDEva-Maria Duerr
Eva-Maria Duerr
MGManish Gala
Manish Gala
JLJingnan Li
Jingnan Li
DCDaniel C Chung
Daniel C Chung

16 January 2007 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
YNY Nakano
Y Nakano
STS Tanno
S Tanno
KKK Koizumi
K Koizumi
TNT Nishikawa
T Nishikawa
KNK Nakamura
K Nakamura
YKY Kohgo
Y Kohgo
To identify predictive molecular markers for gemcitabine resistance, we investigated changes in the expression of four genes associated with gemcitabine transport and metabolism during the development of acquired gemcitabine resistance of pancreatic cancer cell lines. The expression levels of human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), RRM1, and RRM2 mRNA were analysed by real-time light cycler-PCR in various subclones during the development of acquired resistance to gemcitabine. Real-time light cycler-PCR demonstrated that the expression levels of either RRM1 or RRM2 progressively increased during the development of gemcitabine resistance. Expression of dCK was slightly increased in cells resistant to lower concentrations of gemcitabine, but was decreased below the undetectable level in higher concentration-resistant subclones. Expression of hENT1 was increased in the development of gemcitabine resistance. As acquired resistance to gemcitabine seems to correlate with the balance of these four factors, we calculated the ratio of hENT1 × dCK/RRM1 × RRM2 gene expression in gemcitabine-resistant subclones. The ratio of gene expression decreased progressively with development of acquired resistance in gemcitabine-resistant subclones. Furthermore, the expression ratio significantly correlated with gemcitabine sensitivity in eight pancreatic cancer cell lines, whereas no single gene expression level correlated with the sensitivity. These results suggest that the sensitivity of pancreatic cancer cells to gemcitabine is determined by the ratio of four factors involved in gemcitabine transport and metabolism. The ratio of the four gene expression levels correlates with acquired gemcitabine-resistance in pancreatic cancer cells, and may be useful as a predictive marker for the efficacy of gemcitabine therapy in pancreatic cancer patients.

31 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TGTakuma Goto
Takuma Goto
MFMikihiro Fujiya
Mikihiro Fujiya
HKHiroaki Konishi
Hiroaki Konishi
JSJunpei Sasajima
Junpei Sasajima
SFShugo Fujibayashi
Shugo Fujibayashi
TOToshikatsu Okumura
Toshikatsu Okumura
Pancreatic cancer is associated with an extremely poor prognosis, so new biomarkers that can detect the initial stages are urgently needed. The significance of serum microRNA (miR) levels in pancreatic neoplasm such as pancreatic cancer and intraductal papillary mucinous neoplasm (IPMN) diagnosis remains unclear. We herein evaluated the usefulness of miRs enclosed in serum exosomes (ExmiRs) as diagnostic markers. The ExmiRs from patients with pancreatic cancer (n = 32) or IPMN (n = 29), and patients without neoplasms (controls; n = 22) were enriched using ExoQuick-TC™. The expression of ExmiRs was evaluated using a next-generation sequencing analysis, and the selected three miRs through this analysis were confirmed by a quantitative real-time polymerase chain reaction. The expression of ExmiR-191, ExmiR-21 and ExmiR-451a was significantly up-regulated in patients with pancreatic cancer and IPMN compared to the controls (p < 0.05). A receiver operating characteristic curve analysis showed that the area under the curve and the diagnostic accuracy of ExmiRs were 5–20% superior to those of three serum bulky circulating miRs (e.g.; ExmiR-21: AUC 0.826, accuracy 80.8%. Circulating miR-21: AUC 0.653, accuracy 62.3%). In addition, high ExmiR-451a was associated with mural nodules in IPMN (p = 0.010), and high ExmiR-21 was identified as a candidate prognostic factor for the overall survival (p = 0.011, HR 4.071, median OS of high-ExmiR-21: 344 days, median OS of low-ExmiR-21: 846 days) and chemo-resistant markers (p = 0.022). The level of three ExmiRs can thus serve as early diagnostic and progression markers of pancreatic cancer and IPMN, and considered more useful markers than the circulating miRs (limited to these three miRs).

27 July 2007 in Gut
Verified
Journal Article
Closed access
PDF file
STS Tanno
S Tanno
YNY Nakano
Y Nakano
TNT Nishikawa
T Nishikawa
KNK Nakamura
K Nakamura
JSJ Sasajima
J Sasajima
YKY Kohgo
Y Kohgo
Background and aim: Although branch duct intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas without mural nodules are frequently observed in asymptomatic subjects, the natural history of these lesions has never been studied. The aim of this study was to elucidate the natural history of branch duct IPMNs without mural nodules. Methods: Eighty-two patients who had no apparent mural nodules on initial examination were selected for follow-up. All subjects underwent examinations by imaging modalities including endoscopic retrograde pancreatography, and were followed-up by regular examinations once or twice a year. Serial changes of the maximum cystic diameter and the appearance of mural nodules were studied during the observation periods ranging from 14 to 148 months (median, 61 months). Results: Nine (11.0%) of 82 patients exhibited obvious progression of cystic dilatation (median, 59 months). Of these nine patients with cystic enlargement, six continued with regular follow-up examinations. Three cases underwent surgical resection, and were pathologically diagnosed as adenoma in two and borderline in one. Four patients (4.9%) showed newly developed mural nodules in dilated branch ducts (median, 105 months). Histological analysis revealed three cases classified as adenoma and one as carcinoma in situ. None of the remaining 69 patients (84.1%) showed any changes in dilated branch ducts (median, 57 months). Conclusions: Most branch duct IPMNs without mural nodules remained unchanged during long-term follow-up. Although follow-up with careful examination is required to detect newly developed mural nodules in dilated branch ducts, branch duct IPMNs without mural nodules can be followed-up without surgery.

25 June 2018 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
KPKrushna C. Patra
Krushna C. Patra
YKYasutaka Kato
Yasutaka Kato
YMYusuke Mizukami
Yusuke Mizukami
SWSebastian A Widholz
Sebastian A Widholz
MBMyriam Boukhali
Myriam Boukhali
NBNabeel Bardeesy
Nabeel Bardeesy

1 February 2019 in Gastroenterology
Verified
Journal Article
Closed access
YOYuko Omori
Yuko Omori
YOYusuke Ono
Yusuke Ono
MTMishie Tanino
Mishie Tanino
HKHidenori Karasaki
Hidenori Karasaki
HYHiroshi Yamaguchi
Hiroshi Yamaguchi
STShinya Tanaka
Shinya Tanaka